McGinley MP[au] - Search Results

Year	Number of Results
2012	1
2013	1
2016	1
2017	1
2019	2
2020	8
2021	6
2022	5
2023	2

1

Diagnosis and Treatment of Multiple Sclerosis: A Review.

McGinley MP, Goldschmidt CH, Rae-Grant AD. McGinley MP, et al. JAMA. 2021 Feb 23;325(8):765-779. doi: 10.1001/jama.2020.26858. JAMA. 2021. PMID: 33620411 Review.

2

Advances in the Treatment of Multiple Sclerosis.

Goldschmidt C, McGinley MP. Goldschmidt C, et al. Among authors: mcginley mp. Neurol Clin. 2021 Feb;39(1):21-33. doi: 10.1016/j.ncl.2020.09.002. Epub 2020 Nov 7. Neurol Clin. 2021. PMID: 33223085 Free PMC article. Review.

3

Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.

McGinley MP, Cohen JA. McGinley MP, et al. Lancet. 2021 Sep 25;398(10306):1184-1194. doi: 10.1016/S0140-6736(21)00244-0. Epub 2021 Jun 24. Lancet. 2021. PMID: 34175020 Review.

4

Multiple sclerosis management during the COVID-19 pandemic.

Moss BP, Mahajan KR, Bermel RA, Hellisz K, Hua LH, Hudec T, Husak S, McGinley MP, Ontaneda D, Wang Z, Weber M, Tagliani P, Cárdenas-Robledo S, Zabalza A, Arrambide G, Carbonell-Mirabent P, Rodríguez-Barranco M, Sastre-Garriga J, Tintore M, Montalban X, Douglas M, Ogbuokiri E, Aravidis B, Cohen JA, Mowry EM, Fitzgerald KC. Moss BP, et al. Among authors: mcginley mp. Mult Scler. 2020 Sep;26(10):1163-1171. doi: 10.1177/1352458520948231. Epub 2020 Aug 10. Mult Scler. 2020. PMID: 32772807 Free PMC article.

5

The value of patient-reported outcome measures for multiple sclerosis.

McGinley MP, Lapin B. McGinley MP, et al. Mult Scler. 2022 Sep;28(10):1489-1490. doi: 10.1177/13524585221111675. Mult Scler. 2022. PMID: 35876470 Free PMC article. No abstract available.

6

Healthcare utilization in multiple sclerosis: Impact of disease modifying therapies and comorbidities.

Carlson A, McGinley MP. Carlson A, et al. Among authors: mcginley mp. Mult Scler. 2022 Apr;28(4):499-501. doi: 10.1177/13524585221081985. Epub 2022 Mar 16. Mult Scler. 2022. PMID: 35296176 Free PMC article. No abstract available.

7

Safety of monoclonal antibodies for the treatment of multiple sclerosis.

McGinley MP, Moss BP, Cohen JA. McGinley MP, et al. Expert Opin Drug Saf. 2017 Jan;16(1):89-100. doi: 10.1080/14740338.2017.1250881. Epub 2016 Oct 31. Expert Opin Drug Saf. 2017. PMID: 27756172 Review.

8

Myelin oligodendrocyte glycoprotein-IgG associated disorders (MOGAD) following SARS-CoV-2 infection: A case series.

Lambe J, McGinley MP, Moss BP, Mao-Draayer Y, Kassa R, Ciotti JR, Mariotto S, Kunchok A. Lambe J, et al. Among authors: mcginley mp. J Neuroimmunol. 2022 Sep 15;370:577933. doi: 10.1016/j.jneuroim.2022.577933. Epub 2022 Jul 14. J Neuroimmunol. 2022. PMID: 35878436 Free PMC article.

9

Expanded access to multiple sclerosis teleneurology care following the COVID-19 pandemic.

McGinley MP, Gales S, Rowles W, Wang Z, Hsu WY, Amezcua L, Bove R. McGinley MP, et al. Mult Scler J Exp Transl Clin. 2021 Feb 25;7(1):2055217321997467. doi: 10.1177/2055217321997467. eCollection 2021 Jan-Mar. Mult Scler J Exp Transl Clin. 2021. PMID: 33738110 Free PMC article.

10

Teleneurology as a Solution for Outpatient Care During the COVID-19 Pandemic.

McGinley MP, Ontaneda D, Wang Z, Weber M, Shook S, Stanton M, Bermel R. McGinley MP, et al. Telemed J E Health. 2020 Dec;26(12):1537-1539. doi: 10.1089/tmj.2020.0137. Epub 2020 Jun 16. Telemed J E Health. 2020. PMID: 32552509 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results